Topical Nitrogen Mustard in the Management of Mycosis Fungoides

Kim, Youn H.; Martinez, Gina; Varghese, Anna; Hoppe, Richard T.

doi:10.1001/archderm.139.2.165

Cited by 169 publications

(188 citation statements)

References 21 publications

(43 reference statements)

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…31 HN 2 is applied at 0.01% or 0.02% as either an aqueous or ointment-based formulation; both formulations appear to have equivalent efficacy. 15,32,33 The reported probability of hypersensitivity reactions varies from less than 10% to as much as 67%, although these are less likely with the ointment formulation. 15,[32][33][34][35] Therapy is usually continued for 6 months after the clearance of skin lesions.…”

Section: Topical Hn 2 Mechlorethaminementioning

confidence: 99%

See 1 more Smart Citation

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

390

308

View full text Add to dashboard Cite

Section: Topical Hn 2 Mechlorethaminementioning

confidence: 99%

“…The Stanford Group has recently updated their retrospective experience with topical HN 2 : 203 patients with stage I-III disease received HN 2 as first-line therapy. 32 The ORR was 83% and the CR rate 50%. Median time to CR was 10 months for patients with T1 disease and 19 months for those with T2 disease.…”

mentioning

confidence: 92%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

390

308

View full text Add to dashboard Cite

“…Topical corticosteroids produce both clinical and/or pathologic complete remissions in up to 63% of patients with limited patch/ plaque stage MF [205]. Nitrogen mustard (mechlorethamine) may be applied as an aqueous or ointment-based preparation and produces complete remissions in 50-75% of patients with limited patch/plaque stage disease [206,207]. The median time to response is 10-19 months, depending on the extent of disease, with freedom-fromprogression rates exceeding 80% at 10 years [207].…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

“…Nitrogen mustard (mechlorethamine) may be applied as an aqueous or ointment-based preparation and produces complete remissions in 50-75% of patients with limited patch/plaque stage disease [206,207]. The median time to response is 10-19 months, depending on the extent of disease, with freedom-fromprogression rates exceeding 80% at 10 years [207]. Contact hypersensitivity reactions are more common with the aqueous preparation, but occur in fewer than 10% of patients with the ointment-based formulation [207].…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

“…The median time to response is 10-19 months, depending on the extent of disease, with freedom-fromprogression rates exceeding 80% at 10 years [207]. Contact hypersensitivity reactions are more common with the aqueous preparation, but occur in fewer than 10% of patients with the ointment-based formulation [207]. Myelosuppression is not observed.…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract